MannKind (MNKD) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
MannKind (MNKD) Appoints New Chief Medical Officer
August 10, 2015 9:16 AM EDTMannKind (NASDAQ: MNKD) announced the appointment of Dr. Raymond Urbanski as its Chief Medical Officer. As Chief Medical Officer, Dr. Urbanski will lead MannKind's overall drug development activities and will be a member of the Executive Leadership Team.
"Dr.... More



